Journal article
Patient- and Clinician-Reported Outcomes in Human Papillomavirus-Associated Tonsillar Carcinoma Treated With Unilateral and Bilateral Intensity Modulated Radiation Therapy–A Substudy From TROG 12.01
L McDowell, D Rischin, M King, L Kenny, S Porceddu, C Wratten, A Macann, JE Jackson, M Bressel, T Fua, C Lin, C Liu, J Corry
International Journal of Radiation Oncology Biology Physics | Published : 2023
Abstract
Purpose: The aim of this TROG 12.01 substudy was to report longitudinal variations in patient- (PRO) and clinician-reported outcomes based on receipt of unilateral (URT) or bilateral radiation therapy (BRT). Methods and Materials: Patients with lateralized T1-2 N1-2b human papillomavirus-associated tonsillar carcinoma (AJCC7) enrolled on TROG 12.01 were eligible. The primary endpoint was patient-reported radiation symptom severity score (MDASI-RSS) at 2 years, a composite of 9 MDASI-Head and Neck (HN) symptom items. Secondary endpoints included patient-reported symptom burden and interference (MDASI-HN), quality of life (FACT-HN), emotional distress (HADS), return to work (RTW), clinician-re..
View full abstractGrants
Awarded by Roche
Funding Acknowledgements
No external funding was used for this secondary analysis. The original study was funded by the National Health and Medical Research Council (Project Grant 1047673). Cetuximab was supplied by Merck Healthcare Pty Ltd, Macquarie Park, Australia, an affiliate of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945). The health care business of Merck KGaA, Darmstadt, Germany reviewed the manuscript for medical accuracy only before journal submission. The authors are fully responsible for the content of this manuscript and the views and opinions are described in the publication reflect solely those of the authors.